The history of Sildenafil presents a interesting case for observers in the pharmaceutical sector. While initially a blockbuster success, creating vast sums, the patent lapse and the subsequent entry of off-brand versions have significantly impacted earnings. This raises questions about the ongoing viability of related therapeutic projects and sugge